Trusted Resources: Education
Scientific literature and patient education texts
Nusinersen for Spinal Muscular Atrophy in the United States: Findings From a Retrospective Claims Database Analysis
source: Advances in therapy
year: 2021
authors: Gauthier-Loiselle M,Cloutier M,Toro W,Patel A,Shi S,Davidson M,Bischof M,LaMarca N,Dabbous O
summary/abstract:Spinal muscular atrophy (SMA) is a rare, genetic neuromuscular disorder caused by deletion/mutation of the survival motor neuron 1 gene, characterized by progressive loss of motor neurons, resulting in increasing muscular weakness, deteriorating motor function, and, in its most severe form, death before 2 years. Nusinersen, an antisense oligonucleotide that increases expression of the functional SMN protein, was approved for SMA by US and European regulatory agencies in 2016 and 2017, respectively. The indicated regimen requires intrathecal injections every 4 months, following the first four injections during the loading phase. Adherence is integral to treatment success. Adherence to nusinersen may pose particular challenges as most patients with SMA are young children who require complex multidisciplinary care (including ongoing intrathecal treatment administration and potential specialized anesthetic and surgical procedures) at specialized centers. However, real-world data on adherence to nusinersen are limited.
organization: Analysis Group, Inc., 1190 avenue des Canadiens-de-Montréal, Tour Deloitte, Suite 1500, Montreal, QC, Canada.DOI: 10.1007/s12325-021-01938-w
read more
Related Content
-
Comparison of Nusinersen and Evrysdi in the Treatment of Spinal Muscular AtrophySpinal Muscular Atrophy (SMA) is a genet...
-
Sleep Breathing Disorders in Pediatric Patients With Spinal Muscular Atrophy 2Objectives: The study is aimed to analyz...
-
SMA Type 1 – Looking After Your Child Who Has Had a Recent DiagnosisThe aim of everyone involved in your chi...
-
Spinal Muscular Atrophy (SMA)Spinal muscular atrophy (SMA) is a genet...
-
Safety and Efficacy of Once-Daily Risdiplam in Type 2 and Non-Ambulant Type 3 Spinal Muscular Atrophy (SUNFISH Part ...Background: Risdiplam is an oral small m...
-
Despite Taking Spinraza, SMA Type 1 Children Show Nonmotor ProblemsDespite its well-reported benefits in mo...
-
Coverage of Genetic Therapies for Spinal Muscular Atrophy Across Fee-for-Service Medicaid ProgramsBackground: Genetic therapies are a prom...